iCubate® Earns FDA Clearance
iCubate® Earns FDA Clearance for A Unique Diagnostic Solution for the diagnosis of Bloodstream Infections iCubate’s “ARMPCR” technology, integrated platform and initial assay now available for United States Clinical Laboratories Huntsville, Ala. August 10, 2017 – iCubate®, Inc., an innovative molecular diagnostic device company, announced today that it has earned U.S. Food and Drug Administration (FDA) clearance for its iCubate platform, the iC-System™, and its first clinical assay, the iC-GPC Assay™, used for the rapid detection of pathogenic bacteria associated with bloodstream infection (BSI). The FDA clearance allows iCubate to market, sell and distribute the cleared products to U.S. Clinical ...
Read More
Read More
iCubate® forms Scientific Advisory Board
Huntsville, Ala. — October 6, 2016 —iCubate®, a molecular diagnostic company, has formed a Scientific Advisory Board to advance the company’s goal of developing and marketing technologies and products for personalized diagnostics. The advisory board will work with iCubate’s board and management team to ensure the company continues to develop innovative products that meet market demand and are positioned for long-term growth and success. “iCubate is privileged to have these individuals as part of our Scientific Advisory Board. The advice and guidance offered by this group of distinguished scientists will be of tremendous value as we position the company’s future ...
Read More
Read More
FmIH function & proof of concept bladder infections can be reduced!
Researchers have identified a potential way to prevent chronic urinary tract infections (UTIs). Their research points to a key protein that bacteria use to latch onto the bladder and cause UTIs, according to scientists at Washington University School of Medicine in St. Louis. Vaccinating mice against the protein reduces the ability of bacteria to cause severe disease. The study, published Sept. 22 in Cell Host & Microbe, suggests that targeting this protein may prevent the most serious consequences of a very common infection. "Our findings reveal how bacteria have evolved a mechanism to colonize the bladder in order to persist ...
Read More
Read More
iCubate receives Innovation Award at Alabama Launchpad
EDPA’s Alabama Launchpad presents Innovation Awards, celebrates entrepreneurship from Alabama NewsCenter on Vimeo. Andrew Yang, founder and CEO of Venture for America, said during his keynote address that Birmingham is the best-kept secret in the innovation and entrepreneurship world because of the level of support and activity he has witnessed in the Magic City. “It’s phenomenal to see the energy and spirit of entrepreneurship really coming into its own here in Birmingham,” Yang said. Venture for America, or VFA, works with existing innovation companies and startups by offering fellowships to recent college graduates to help them learn what it takes ...
Read More
Read More
Winners of 2016 Alabama Innovation Awards announced
One company provides physicians real-time patient-information about cost and risk data. One company has developed software concepts, designs and prototypes for the aerospace and defense biomedical industries. One is a shipbuilding company. Another is a molecular diagnostic company. And one is a north Alabama businessman who has been a major influence on Florence area startups, as well as industries nationally and internationally. They are all Alabama Innovation Awards winners. The Economic Development Partnership of Alabama Monday announced the winners of its 2016 Alabama Innovation Awards. "These awards reflect EDPA's commitment to encourage and celebrate innovation-based economic development across Alabama," said ...
Read More
Read More
The Guesswork Is Almost Over
Laura Freeman May 12, 2016 iCubate founder Jian Han, MD, PhD holds the iCubate cassette. Instead of waiting for cultures and plate counts, soon iCubate DNA assays could be telling you exactly what gram positive bacteria you are fighting. The iCubate iC-GPC Assay developed in Huntsville has passed beta testing in three U.S. hospitals with flying colors, and following clinical trials for FDA approval, it could be available for use in patient care within a year. “With one blood sample, the assay can test for multiple molecular targets and for antibiotic resistance. It enables physicians to ask better questions—not simply ...
Read More
Read More
Test to diagnose “normal” health could help re-focus medical system on prevention.
By: Cathy Yarbrough, contributing science writer Jian Han, MD, PhD, envisions a future when medical check-ups will include a test to determine your health index – a measure of your immune system’s readiness to ward off invading viruses. Han described his ideas at the HudsonAlpha Institute for Biotechnology’s 2015 Immunogenomics conference, held in late September in Huntsville, Ala. A health index based on the strength of the immune system will enable doctors to diagnose normal health as well as disease, said Han, who is a faculty investigator at HudsonAlpha. “The U.S. health care system is often criticized as overly focused ...
Read More
Read More
iCubate data presented at American Society of Microbiology meeting
New Orleans, La. — During the 115th General Meeting of the American Society of Microbiology, iCubate® Inc., in conjunction with expert microbiologists representing clinical laboratories from around the U.S., released positive pre-clinical data on the company’s diagnostic test for blood stream infection. The data were generated at the following sites: Dynacare Laboratories/Medical College of Wisconsin in Milwaukee, Wis.; the Laboratory Alliance of Central New York in Liverpool, N.Y.; and University of New Mexico Health Sciences Center/TriCore Reference Laboratories in Albuquerque, N.M. According to the publication, “Early identification of the organism(s) present in positive blood culture bottles and genetic determinants associated ...
Read More
Read More
